Cosentyx (secukinumab) has potential interactions with other prescription medications and certain vaccines. For example, Cosentyx may interact with cyclosporine and other immunosuppressant drugs and ...
EAST HANOVER, N.J., Oct. 2, 2019 /PRNewswire/ -- Novartis, a leader in rheumatology and immuno-dermatology, today announced additional positive data from the PREVENT trial, evaluating the efficacy and ...
The Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) injections for treating various inflammatory conditions in adults and, in some cases, children. Cosentyx may treat moderate ...
The approval was based on data from the phase 3 SUNSHINE and SUNRISE trials, which included 1084 adults with moderate to severe HS. Results showed a significantly greater proportion of patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results